Renouvellement de l'autorisation d’accès précoce à la spécialité SKYCLARYS (omaveloxolone) dans l’indication « traitement de l’ataxie de Friedreich (AF) chez les adultes et les adolescents âgés de 16 ans et plus ».
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
NB7YzsXMkeccxAqp
Écouter
